Canntab Therapeutics Limited
PILL.CN
Canadian Securities Exchange0.01
CAD
+0.00
- -
Canntab Therapeutics Limited
PILL.CN
(Canadian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Canntab Therapeutics Limited (CSE:PILL) is a Canadian phytopharmaceutical company engaged in the research, development, and manufacturing of advanced pharmaceutical-grade cannabinoid formulations in solid oral dosage forms. The company offers a suite of precision oral dose products, including sustained release cannabinoid formulations and pellets; immediate release cannabidiol formulations; modified-release multi-layer cannabinoid formulations; flash-melt cannabinoid formulations; bi-layer cannabinoid tablets; extended release tablets; nanoemulsion technology; multi-particulate drug delivery systems; specialty gel capsules; proprietary granulation technology; oral quick dissolve tablets; and instant release, extended release, and bi-layer solid oral formulations containing THC, CBD, and terpenoids for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management, appetite loss associated with cancer treatments, and opioid addiction therapy. Founded in 2016 and headquartered at 223 Riviera Drive in Markham, Ontario, Canntab operates primarily in Canada with distribution channels targeting international markets including Australia, Germany, and the United States. Recent developments include receipt of a Health Canada export license approval, a strategic partnership with Levitee Clinics to provide opiate alternatives, an agreement with 36eight Technologies Inc. for bioinformatics collaboration as of October 2021, and submission of a site evidence package to Health Canada in December 2019 for licensing its Markham facility to commence manufacturing in late 2020.